Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àª½¼º´ ȯÀÚ¿¡¼­ D-penicillamine Ä¡·á Áß ¹ß»ýÇÑ ¹Ì¼¼º¯È­Çü ½ÅÁõÈıº 1·Ê A Case of Minimal Change Nephrotic Syndrome Associated with D-penicillamine Therapy of Wilson¡¯s Disease

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2002³â 5±Ç 2È£ p.206 ~ 211
¿À±â¿ø, ±è¼¼¿µ, ÀÌȯ¼®, ÃÖº´È£, °íö¿ì, ±¸ÀÚÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
¿À±â¿ø ( Oh Ki-Won ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

±è¼¼¿µ ( Kim Se-Young ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌȯ¼® ( Lee Hwan-Seok ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÃÖº´È£ ( Choe Byung-Ho ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
°íö¿ì ( Ko Cheol-Woo ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±¸ÀÚÈÆ ( Koo Ja-Hoon ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

Àª½¼º´ÀÇ Ä¡·áÁ¦·Î ±¸¸® ÈíÂøÁ¦ÀÎ D-penicillamineÀÌ ÁÖ·Î »ç¿ëµÇ°í ÀÖÀ¸³ª, ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ¹ß»ýÇÒ °æ¿ì Åõ¾àÀ» Áß´ÜÇÏ°í trientine µîÀ» ´ëü¾àÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Ù. ÀúÀÚµéÀº Àª½¼º´À¸·Î D-penicillamine »ç¿ë µµÁß 6°³¿ù¸¸¿¡ ¹Ì¼¼º¯È­Çü ½ÅÁõÈıºÀÌ ¹ß»ýÇÑ ÈÄ trientineÀ¸·Î Ä¡·á¾àÀ» ´ëü ÈÄ °üÇØ°¡ À¯µµµÈ 1·Ê¸¦ °æÇèÇÏ¿´±â¿¡ º¸°íÇÏ´Â ¹ÙÀÌ´Ù.

Wilson¡¯s disease is a treatable autosomal recessive inherited disorder of copper metabolism due to mutation of the copper transporting gene. The basic strategy of treatment is to reduce the amount of copper in the liver and other tissues by
administering both a low copper diet and copper-chelating agents. D-penicillamine is the first choice as a copper-chelating agent. Some serious side effects could occur in 3¡­5% of all patients following D-penicillamine therapy. We report a 19 year-old male with Wilson¡¯s disease who developed nephrotic syndrome 6 months after the initiation of D-penicillamine therapy. Prednisolone was administered to control nephrotic syndrome and D-penicillamine was switched to trientine. Urinary remission was achieved within a week and maintained thereafter. Nephrotic syndrome was proven to be MCNS by kidney biopsy.

Å°¿öµå

Wilson¡¯s disease;D-penicillamine;Side effect;Nephrotic syndrome;Trientine;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS